These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29651748)

  • 1. Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
    El Amki M; Lerouet D; Garraud M; Teng F; Beray-Berthat V; Coqueran B; Barsacq B; Abbou C; Palmier B; Marchand-Leroux C; Margaill I
    Mol Neurobiol; 2018 Dec; 55(12):9156-9168. PubMed ID: 29651748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
    Haddad M; Beray-Berthat V; Coqueran B; Plotkine M; Marchand-Leroux C; Margaill I
    Fundam Clin Pharmacol; 2013 Aug; 27(4):393-401. PubMed ID: 22436003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
    Teng F; Beray-Berthat V; Coqueran B; Lesbats C; Kuntz M; Palmier B; Garraud M; Bedfert C; Slane N; Bérézowski V; Szeremeta F; Hachani J; Scherman D; Plotkine M; Doan BT; Marchand-Leroux C; Margaill I
    Exp Neurol; 2013 Oct; 248():416-28. PubMed ID: 23876515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
    Abdelkarim GE; Gertz K; Harms C; Katchanov J; Dirnagl U; Szabó C; Endres M
    Int J Mol Med; 2001 Mar; 7(3):255-60. PubMed ID: 11179503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
    El Amki M; Lerouet D; Coqueran B; Curis E; Orset C; Vivien D; Plotkine M; Marchand-Leroux C; Margaill I
    Exp Neurol; 2012 Dec; 238(2):138-44. PubMed ID: 22921458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
    Crome O; Doeppner TR; Schwarting S; Müller B; Bähr M; Weise J
    J Neurosci Res; 2007 Jun; 85(8):1734-43. PubMed ID: 17455321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Functions of PJ34, a Poly(ADP-ribose) Polymerase Inhibitor, Are Related to Down-Regulation of Calpain and Nuclear Factor-κB in a Mouse Model of Traumatic Brain Injury.
    Tao X; Chen X; Hou Z; Hao S; Liu B
    World Neurosurg; 2017 Nov; 107():888-899. PubMed ID: 28642177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant tissue plasminogen activator enhances microparticle release from mouse brain-derived endothelial cells through plasmin.
    Garraud M; Khacef K; Vion AC; Leconte C; Yin M; Renard JM; Marchand-Leroux C; Boulanger CM; Margaill I; Beray-Berthat V
    J Neurol Sci; 2016 Nov; 370():187-195. PubMed ID: 27772757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pinocembrin Protects Blood-Brain Barrier Function and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in a Rat Thromboembolic Stroke Model.
    Ma Y; Li L; Kong L; Zhu Z; Zhang W; Song J; Chang J; Du G
    Biomed Res Int; 2018; 2018():8943210. PubMed ID: 29850586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
    Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
    Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
    Yang Y; Li Q; Yang T; Hussain M; Shuaib A
    J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice.
    Haddad M; Beray-Berthat V; Coqueran B; Palmier B; Szabo C; Plotkine M; Margaill I
    Eur J Pharmacol; 2008 Jun; 588(1):52-7. PubMed ID: 18468597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LOX-1 and MMP-9 Inhibition Attenuates the Detrimental Effects of Delayed rt-PA Therapy and Improves Outcomes After Acute Ischemic Stroke.
    Arkelius K; Wendt TS; Andersson H; Arnou A; Gottschalk M; Gonzales RJ; Ansar S
    Circ Res; 2024 Apr; 134(8):954-969. PubMed ID: 38501247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective actions of PJ34, a poly(ADP-ribose)polymerase inhibitor, on the blood-brain barrier after traumatic brain injury in mice.
    Tao X; Chen X; Hao S; Hou Z; Lu T; Sun M; Liu B
    Neuroscience; 2015 Apr; 291():26-36. PubMed ID: 25668593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Reduces Brain Damage after Stroke in the Neonatal Mouse Brain.
    Bonnin P; Vitalis T; Schwendimann L; Boutigny A; Mohamedi N; Besson VC; Charriaut-Marlangue C
    Curr Issues Mol Biol; 2021 Jun; 43(1):301-312. PubMed ID: 34200155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
    You YP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):990-7. PubMed ID: 26851971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cav-1 Protein Levels in Serum and Infarcted Brain Correlate with Hemorrhagic Volume in a Mouse Model of Thromboembolic Stroke, Independently of rt-PA Administration.
    Gubern-Mérida C; Comajoan P; Huguet G; García-Yebenes I; Lizasoain I; Moro MA; Puig-Parnau I; Sánchez JM; Serena J; Kádár E; Castellanos M
    Mol Neurobiol; 2022 Feb; 59(2):1320-1332. PubMed ID: 34984586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Another "string to the bow" of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism?
    Lechaftois M; Dreano E; Palmier B; Margaill I; Marchand-Leroux C; Bachelot-Loza C; Lerouet D
    PLoS One; 2014; 9(10):e110776. PubMed ID: 25329809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia.
    Greco R; Tassorelli C; Mangione AS; Levandis G; Certo M; Nappi G; Bagetta G; Blandini F; Amantea D
    Eur J Pharmacol; 2014 Dec; 744():91-7. PubMed ID: 25446913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury.
    Park EM; Cho S; Frys K; Racchumi G; Zhou P; Anrather J; Iadecola C
    Stroke; 2004 Dec; 35(12):2896-901. PubMed ID: 15514191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.